James Baker, speaking at World Influenza Congress Europe 2011

James Baker,
CEO
Nanobio Corporation

Dr. Baker is the inventor of the platform technology, founder of NanoBio and an internationally recognized expert in immunology and nanotechnology. Dr. Baker invented the NanoStat technology at the University of Michigan, where he is the Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the Medical School. As the Director of the University of Michigan Nanotechnology Institute, Dr. Baker leads a multidisciplinary team of 30 scientists focused on the use of nanotechnology in biomedical applications. He is one of three editors of the National Nanotechnology Initiative’s Research Directives, and a member of the Nanotechnology for Medicine and Biology study section at National Institutes of Health (“NIH”). Dr. Baker is a board-certified internist, allergist and immunologist, a member of American Board of Allergy and Immunology and a Fellow of the American College of Physicians. He is also a Fellow of the American Academy for the Advancement of Science.

Appearing:

Congress Day 3 – Thursday 8th December 2011

9.40am

Triggering robust immunity using significantly less antigen through Nanoemulsion-based intranasal vaccine adjuvants

What are the key nanoemulsion characteristics and mechanisms of action?
Uptake into dendritic cells, systemic distribution of the nanoemulsions, Th1-biased immune response and non inflammatory immune response
Efficacy of nasal nanoemulsion-based influenza vaccines in animal models and other examples of successful nanoemulsion-vaccine models

James Baker,

CEO,
Nanobio Corporation

Sponsor World Influenza Congress Europe 2011 ›

Silver Sponsor